MX2022005234A - Derivados de isoquinolinona, procedimiento para su preparacion y composicion farmaceutica para la prevencion o el tratamiento de enfermedades relacionadas con la poli(adp-ribosa) polimerasa-1, que constituye los mismos como principio activo. - Google Patents

Derivados de isoquinolinona, procedimiento para su preparacion y composicion farmaceutica para la prevencion o el tratamiento de enfermedades relacionadas con la poli(adp-ribosa) polimerasa-1, que constituye los mismos como principio activo.

Info

Publication number
MX2022005234A
MX2022005234A MX2022005234A MX2022005234A MX2022005234A MX 2022005234 A MX2022005234 A MX 2022005234A MX 2022005234 A MX2022005234 A MX 2022005234A MX 2022005234 A MX2022005234 A MX 2022005234A MX 2022005234 A MX2022005234 A MX 2022005234A
Authority
MX
Mexico
Prior art keywords
parp
pharmaceutical composition
active ingredient
same
adp
Prior art date
Application number
MX2022005234A
Other languages
English (en)
Inventor
Eunhee Kim
Changmin Park
Sehwan Oh
Younghoon Kim
Juhee Lee
Jaehee Seol
Ahram Shim
Younggwan Kim
Tae-Sung Koo
Ki-Hong Jang
Original Assignee
Digmbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digmbio Inc filed Critical Digmbio Inc
Publication of MX2022005234A publication Critical patent/MX2022005234A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a derivados de isoquinolinona, un procedimiento para preparar los mismos y una composición farmacéutica para la prevención o tratamiento de enfermedades relacionadas con la poli(ADP-ribosa) polimerasa-1 (PARP-1) que contiene los mismos como ingrediente activo. Los derivados de isoquinolinona exhiben un excelente efecto inhibidor de PARP-1 a una concentración de unidades nanomolares y de manera adicional exhiben un excelente efecto citoprotector (efecto inhibidor de la apoptosis) sobre enfermedades o trastornos oftálmicos, específicamente trastornos de la retina, y por lo tanto pueden usarse eficazmente como una composición farmacéutica para la prevención o tratamiento de enfermedades relacionadas con PARP-1, por ejemplo, enfermedades o trastornos oftálmicos, los cuales contienen los mismos como ingrediente activo.
MX2022005234A 2019-10-30 2020-10-29 Derivados de isoquinolinona, procedimiento para su preparacion y composicion farmaceutica para la prevencion o el tratamiento de enfermedades relacionadas con la poli(adp-ribosa) polimerasa-1, que constituye los mismos como principio activo. MX2022005234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190136798 2019-10-30
PCT/KR2020/014947 WO2021086077A1 (ko) 2019-10-30 2020-10-29 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2022005234A true MX2022005234A (es) 2022-09-07

Family

ID=75715420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005234A MX2022005234A (es) 2019-10-30 2020-10-29 Derivados de isoquinolinona, procedimiento para su preparacion y composicion farmaceutica para la prevencion o el tratamiento de enfermedades relacionadas con la poli(adp-ribosa) polimerasa-1, que constituye los mismos como principio activo.

Country Status (11)

Country Link
US (1) US20230027362A1 (es)
EP (1) EP4053106A4 (es)
JP (1) JP7512380B2 (es)
KR (1) KR102293986B1 (es)
CN (1) CN114929673A (es)
AU (1) AU2020376697B2 (es)
BR (1) BR112022008282A2 (es)
CA (1) CA3158807A1 (es)
IL (1) IL292466A (es)
MX (1) MX2022005234A (es)
WO (1) WO2021086077A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
WO2002094790A1 (fr) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
CN100390164C (zh) 2002-10-01 2008-05-28 三菱制药株式会社 异喹啉化合物及其医药用途
JP2009196973A (ja) * 2007-09-26 2009-09-03 Santen Pharmaceut Co Ltd キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
RU2696572C2 (ru) * 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
MX2018005515A (es) 2015-11-02 2018-08-01 Merck Patent Gmbh Derivados de 1,4-dicarbonil-piperidilo.
KR102030016B1 (ko) 2016-09-05 2019-10-08 충남대학교산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
MA47165B1 (fr) * 2016-12-30 2021-06-30 Mitobridge Inc Inhibiteurs de la poly-adp-ribose polymérase (parp)
KR102017115B1 (ko) * 2018-05-15 2019-09-02 충남대학교산학협력단 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
US20230027362A1 (en) 2023-01-26
AU2020376697A1 (en) 2022-05-19
CA3158807A1 (en) 2021-05-06
JP2023506368A (ja) 2023-02-16
KR20210052330A (ko) 2021-05-10
BR112022008282A2 (pt) 2022-07-26
IL292466A (en) 2022-06-01
WO2021086077A1 (ko) 2021-05-06
EP4053106A4 (en) 2023-12-06
CN114929673A (zh) 2022-08-19
AU2020376697B2 (en) 2024-03-14
EP4053106A1 (en) 2022-09-07
KR102293986B1 (ko) 2021-08-26
JP7512380B2 (ja) 2024-07-08

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2016137235A3 (ko) 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물
SG10201902664RA (en) Combination therapy for treating cancer
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
PH12020550491A1 (en) Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
WO2015058664A8 (zh) 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
MX2021011488A (es) Compuestos y usos de estos.
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
MX2016005883A (es) Formulaciones de acido poliinosinico-policitidilico (poli (i:c))para el tratamiento de infecciones del tracto respiratorio superior.
MY193529A (en) Ophthalmologic pharmaceutical composition
MX2024006768A (es) Compuestos y usos de los mismos.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
WO2018074862A3 (ko) Tha를 유효성분으로 포함하는 유방암 치료용 약학적 조성물
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2022005234A (es) Derivados de isoquinolinona, procedimiento para su preparacion y composicion farmaceutica para la prevencion o el tratamiento de enfermedades relacionadas con la poli(adp-ribosa) polimerasa-1, que constituye los mismos como principio activo.
PH12017502145A1 (en) Composition and uses thereof
WO2014116015A3 (ko) 자죽염을 포함하는 알츠하이머병 예방용 조성물 및 자죽염의 제조방법
MX2018011422A (es) Farmaco de sal cristalina de clorhidrato para tratar o prevenir enfermedad asociada con janus cinasas (jak) y su metodo de preparacion.
BR112021017829A2 (pt) Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.